View Full Version : Cellular Matrices And Tissue Scaffolds Providing An Evolving Solution To Refractory

Medical Videos
03-31-2007, 06:05 AM
Cellular Matrices And Tissue Scaffolds Providing An Evolving Solution To Refractory Wounds

Wound care treatments that mimic the body's natural physiology and/or regenerative pathways - technologies that include tissue-engineered skin substitutes, regeneration matrices, and biologically active cellular therapies - are making strides in clinical trial settings and are on track to change the way difficult-to-treat wounds are managed. Refractory wounds represent the largest single segment for advanced wound care in terms of treatment costs, followed by burn treatment and surgical wound applications. Within the refractory wound segment, diabetic ulcers represent slightly less than three-quarters of the current market (treatment cost basis). The remainder of the refractory wound market consists of pressure ulcers and other-non-healing wounds.

Emerging products and processes for wound management and wound repair include a number of synthetic and bioengineered products that have recently become available, or are being developed, as adjuncts to wound care and/or as a replacement for human skin. Several polypeptide growth factors have been identified in the wound healing process, including platelet-derived growth factor, epidermal growth factor, fibroblast growth factors, transforming growth factors and insulin-like growth factor. With no clear leader currently in the emerging bioengineered wound care market segment, we expect the next twenty-four months to determine which company or companies will become a major presence. This sector will experience impressive growth.

These bioengineered products and therapies will be competing in a worldwide market worth billions, and in which improvements in quality-of-life and treatment outcomes continue to be top healthcare industry initiatives. "This is a market that is experiencing unabated growth, as the aging of populations in developed countries leads to increasing caseloads of chronic wounds due to disease and immobility," explains George Perros, Greystone's Managing Director.

While pricing for this new generation of products represents a significant premium relative to existing wound care products, recent studies indicate their ability to promote healing in otherwise refractory wounds places them on a competitive plane in terms of total cost of treatment.

These findings are contained in a new and comprehensive report: Bioengineered Wound Care: Products, Players, and Prospects. The report provides a detailed analysis of twenty-two bioengineered wound care products, and profiles companies active in the advanced wound care therapeutics sector.

More information is available at http://www.applieddata.org.

About Applied Data

Applied Data Research is a drug therapeutics consulting firm focused on medical market strategies, product commercialization, venture development, and market research. We assist medical market participants in achieving their business objectives through the creation of detailed business development strategies, product commercialization programs, and comprehensive market and technology research and analysis